BELITE BIO, INC (BLTE) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-08

Key Insights

Chief Scientific Officer Nathan L. Mata executed a significant sale of 666 American Depositary Shares on 05/07/2026 through a pre-planned Rule 10b5-1 trading plan adopted on 12/10/2025, reducing his beneficial ownership to 9 shares.
The sales were executed at relatively stable prices ranging from $152.35 to $155.29, with weighted average prices between $152.45 and $155.25, suggesting orderly execution without signs of distress selling.
The use of a Rule 10b5-1 trading plan indicates this was a pre-planned, systematic divestment rather than a reactive decision, which typically reduces insider trading concerns but suggests confidence in predetermined liquidity needs.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-07

Chief Scientific Officer Nathan L. Mata executed a substantial sale of 900 American depositary shares on May 6, 2026, totaling approximately $137,000 at prices ranging from $151.17 to $156.00, reducing his holdings from 2,566 to 1,666 shares.
The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating this was a pre-planned divestment rather than a reactive market timing decision, which reduces but does not eliminate insider selling concerns.
The multiple tranches sold at progressively higher prices ($151.57 to $156.00) suggest an organized liquidation strategy, and the significant reduction in beneficial ownership by a C-suite executive could signal reduced confidence or personal liquidity needs.
As Chief Scientific Officer, Mata's departure from meaningful share ownership is noteworthy given his critical role in the company's R&D strategy, though the pre-planned nature of the sales limits negative inference.

Filed: 2026-05-06

Chief Scientific Officer Nathan L. Mata executed a significant insider sale of 1,000 shares across five tranches on 05/05/2026 under a Rule 10b5-1 trading plan adopted on 12/10/2025, totaling approximately $155,000 in proceeds at average prices ranging from $153.92 to $158.11.
The sales were conducted via a pre-established trading plan, indicating the transactions were planned in advance rather than reactive to market conditions, which reduces concerns about insider panic selling or negative company sentiment.
Following these sales, Mata retains 1,666 beneficial shares of BLTE, suggesting he maintained a meaningful ownership stake despite the liquidation activity, though the reduction from 2,666 shares represents a 37.5% decrease in his direct holdings.

Filed: 2026-05-05

Chief Scientific Officer Nathan L. Mata executed a significant sale of 1,000 shares of BLTE on 05/04/2026 across five tranches at prices ranging from $153.05 to $157.98, reducing his beneficial ownership from approximately 3,634 to 2,666 shares.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on 12/10/2025, indicating this was a pre-planned divestment rather than an opportunistic or reactive sale decision.
The consistent upward pricing across the five sale tranches ($153-$158 range) suggests strong stock performance at the time of sale, though insider selling by a C-suite executive could signal confidence limitations or portfolio rebalancing rather than bullish conviction.

Filed: 2026-05-01

Chief Scientific Officer Nathan L. Mata executed a significant insider sale of 1,000 American depositary shares (total of 42+517+340+101 shares across tranches) on April 30, 2026, at prices ranging from $155.62 to $158.42 per share, reducing his beneficial ownership from approximately 5,624 to 4,666 shares.
The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating these were pre-planned transactions designed to avoid insider trading concerns rather than opportunistic selling driven by recent developments.
The weighted average selling prices across four separate tranches ($155.68 to $158.15) suggest deliberate execution across a price range, consistent with a systematic liquidation plan rather than panic selling or market timing concerns.

Filed: 2026-04-30

Chief Scientific Officer Nathan L. Mata executed a substantial sale of 1,000 shares of BELITE BIO stock on 04/29/2026, reducing his beneficial ownership from approximately 6,688 shares to 5,666 shares, representing a 15% reduction in his holdings.
The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on 12/10/2025, indicating this was a pre-planned, systematic divestment rather than an opportunistic trade, which reduces concerns about sudden loss of confidence but suggests long-term rebalancing.
Share prices during the sale ranged from approximately $154.22 to $158.21, showing stable to slightly increasing valuations across the transaction window, with the officer selling at progressively higher price points across multiple tranches.

Filed: 2026-04-29

Chief Scientific Officer Nathan L. Mata executed a substantial sale of 1,000 American depositary shares on 04/28/2026 through a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, reducing his beneficial ownership from 7,654 to 6,666 shares.
The sales were executed across nine separate transactions with prices ranging from $154.62 to $162.59, suggesting a methodical accumulation-to-disposition strategy rather than a panic sell, which is more typical of pre-planned diversification.
The pre-planned nature of these sales (established over 4 months prior in December 2025) indicates the transactions were not reactive to recent company developments or negative information, reducing concerns about insider loss of confidence.

Filed: 2026-04-28

Chief Scientific Officer Nathan L. Mata executed a substantial sale of 1,000 American depositary shares (44+280+231+409+36) on April 27, 2026, reducing his beneficial ownership from 8,622 to 7,666 shares, representing a 11% reduction in his position.
The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating a pre-planned divestment strategy rather than opportunistic selling, which reduces the immediate negative signal but still represents insider selling.
Share prices during the sale ranged from $160.54 to $164.59, suggesting a gradual accumulation of sell orders executed at favorable prices across multiple price points throughout the trading window.
As Chief Scientific Officer, Mata's significant insider selling may warrant investor attention regarding management's confidence in the company's near-term prospects or potential liquidity needs, though the pre-planned nature mitigates some concerns.

Filed: 2026-04-27

Chief Scientific Officer Nathan L. Mata executed a substantial sale of 1,000 American depositary shares on 04/24/2026 through a pre-established Rule 10b5-1 trading plan adopted on 12/10/2025, reducing his beneficial ownership from approximately 9,592 shares to 8,666 shares.
The sales were executed across multiple tranches at incrementally increasing prices ranging from $157.81 to $162.53, suggesting systematic liquidation rather than panic selling, with weighted average prices indicating strong stock performance during the transaction period.
The use of a pre-planned Rule 10b5-1 trading arrangement indicates this was a scheduled, non-discretionary transaction likely for personal liquidity needs rather than a loss of confidence signal, reducing insider selling concerns.

Filed: 2026-04-24

Nathan L. Mata, Chief Scientific Officer, executed a substantial sale of 1,000 American depositary shares on 04/23/2026 through a pre-planned Rule 10b5-1 trading plan adopted on 12/10/2025, reducing his beneficial ownership from approximately 10,399 to 9,666 shares.
The sales were executed across six tranches at incrementally increasing prices ranging from $164.03 to $169.69, with total proceeds approximately $166,000-$167,000, suggesting the executive was systematically liquidating shares rather than responding to immediate liquidity needs.
The use of a Rule 10b5-1 trading plan indicates this was a pre-planned, non-discretionary sale initiated well in advance (over 4 months prior), which typically reduces concerns about insider knowledge of negative developments.

Filed: 2026-04-23

Chief Medical Officer Hendrik Peter Scholl received a vesting of 10,000 ordinary shares worth approximately $774,000 (at $77.40 exercise price) on April 21, 2026, based on performance criteria being met, indicating positive progress on company objectives.
The option was originally granted on October 7, 2025, with a 9.5-year expiration date (October 6, 2035), suggesting the company is using equity compensation to retain key medical leadership in what appears to be a long-term strategic role.
The indirect beneficial ownership through Bioptima Ltd. suggests a structured ownership arrangement, which may indicate corporate governance considerations or tax planning typical for international executives.

Filed: 2026-04-23

CEO Yu-Hsin Lin acquired 10,000 ordinary shares on April 21, 2026, through vesting of restricted stock units (RSUs) granted on September 15, 2025, bringing total beneficial ownership to 182,949 shares.
The RSU vesting was contingent on performance criteria that were satisfied on April 21, 2026, suggesting the company met predetermined performance milestones and the CEO achieved vesting targets.
This is a non-discretionary equity acquisition resulting from a pre-existing compensation plan rather than open market buying, indicating no signal of insider confidence or conviction about stock direction at current prices.

Filed: 2026-04-23

Nathan L. Mata, Chief Scientific Officer of Belite Bio, executed a significant sale of 880 American depositary shares on April 22, 2026, through a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025, reducing his holdings from approximately 11,635 to 10,666 shares.
The sales were executed across multiple tranches at incrementally higher prices ranging from $165.64 to $173.16, suggesting a systematic liquidation schedule rather than a reaction to negative company news, which is typical of pre-planned trading arrangements.
As Chief Scientific Officer and a company insider, this substantial stock sale of nearly 8% of his beneficially owned position may signal reduced confidence in near-term stock appreciation or could reflect personal liquidity needs rather than fundamental concerns about the company.

Filed: 2026-04-23

CFO Chuang Hao-Yuan acquired 10,000 ordinary shares on April 21, 2026, through vesting of restricted stock units granted on September 15, 2025, indicating performance-based compensation tied to achievement of specific milestones.
The acquisition was made at $0 price per share, which is typical for RSU vesting and represents no additional capital commitment by the insider, suggesting this was a predetermined equity compensation arrangement.
Following the transaction, the CFO beneficially owns 205,264 ordinary shares directly, demonstrating continued material stake in the company and alignment with shareholder interests.

Filed: 2026-04-22

Chief Scientific Officer Nathan L. Mata executed a significant insider sale of 1,000 American depositary shares (ADS) on 04/21/2026 through a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, reducing his beneficial ownership from approximately 12,602 to 11,666 shares.
The sales were executed across five tranches at progressively higher prices ranging from $163.26 to $167.94, with weighted average prices between $163.49 and $167.34, suggesting the stock experienced upward price momentum during the trading day.
The use of a Rule 10b5-1 trading plan indicates this was a pre-planned, systematic divestiture rather than a reactive sell-off, which reduces concerns about negative insider sentiment but suggests liquidity needs or portfolio rebalancing by the CSO.
Following the transactions, Mata retained 11,666 shares in direct beneficial ownership, indicating he maintains a meaningful stake in the company despite the sale.

Filed: 2026-04-21

Chief Scientific Officer Nathan L. Mata executed a systematic sell-off of 980 American depositary shares on April 20, 2026, at prices ranging from $162.01 to $168.43, reducing his holdings from approximately 13,671 to 12,691 shares.
The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating pre-planned, non-discretionary insider trading rather than reactive market timing.
The weighted average sale prices across multiple tranches ($162.76 to $168.35) suggest the executive systematically liquidated shares throughout the trading day, capturing a modest price appreciation of approximately $6.34 per share during execution.
As Chief Scientific Officer, Mata retains significant direct ownership of 12,691 shares post-transaction, indicating maintained confidence in the company despite the divestment activity.

Filed: 2026-04-16

The reporting person, Nathan L. Mata, who is the Chief Scientific Officer, has sold a total of 1,000 American depositary shares (ADS) of Belite Bio, Inc. (BLTE) on April 15, 2026 at weighted average prices ranging from $167.58 to $171.19 per ADS.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025, indicating a planned and systematic approach to the transaction.
The reporting person's beneficial ownership of BLTE ADSs has decreased from 16,283 to 15,666 as a result of the reported sales, representing a roughly 4% reduction in their total holdings.

Filed: 2026-04-13

Yu-Hsin Lin, the CEO of Belite Bio, Inc. (BLTE), has sold a total of 9,200 American Depositary Shares (ADSs) on April 9, 2026, representing a 3.3% reduction in his direct beneficial ownership.
The sales were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating a planned and orderly sell-down rather than a reactive transaction.
The selling prices ranged from $180.00 to $183.00 per ADS, suggesting the CEO may have been locking in gains or diversifying his portfolio.

Filed: 2026-04-13

Wan-Shan Chen, a director of Belite Bio, Inc., has sold 1,100 American Depositary Shares (ADS) of the company at an average price of $180.43 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025, indicating a pre-planned transaction.
Following the reported transaction, Wan-Shan Chen still holds 9,096 ADS of Belite Bio, Inc., maintaining a significant ownership stake in the company.

Filed: 2026-04-13

The filing indicates that Hao-Yuan Chuang, the Chief Financial Officer of Belite Bio, Inc. (BLTE), has sold a total of 6,200 American depositary shares (ADSs) of the company on April 9, 2026.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted by Chuang on December 22, 2025, suggesting a pre-planned nature of the transactions.
The reported transactions represent a significant reduction in Chuang's beneficial ownership of Belite Bio's ADSs, from 100,000 shares to 93,800 shares.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.